Amgen stock: Q3 date adds a fresh catalyst before November

Amgen has set a concrete date for its next financial update, giving investors a new near-term event to monitor. In a release dated October 28, 2026, Amgen said it will report third-quarter 2026 results on November 3 after the close of U.S. markets.

The release adds that the conference call will begin at 4:30 p.m. Eastern Time. Chairman and Chief Executive Officer Robert A. Bradway and other members of senior management are scheduled to participate, while the webcast will be open to investors, media and the general public.

What has changed since the last report

The announcement is a new calendar detail following the most recent relevant report on Amgen's clinical pipeline and dividend timetable. It gives the market a defined date for the next test of operating performance, including the company's ability to balance commercial momentum with investment in its development pipeline.

Amgen's current Lang & Schwarz quote was EUR 413.03 at 16:08:35 Berlin time on October 29, 2026. That is 2.99 percent above the EUR 401.05 quote recorded at 11:10 Berlin time in the read report published on October 28, 2026. This is a separate comparison from any Xetra session-to-session performance.

The real-time quote of Amgen stock provides the continuously updated Berlin reference. The webcast timing does not itself indicate the direction of the next share-price move; investors will likely focus on reported results, management commentary and the outlook.

Amgen is part of a broader U.S. equity market whose risk appetite can influence the trading backdrop for large-cap healthcare companies. Current market reports provide the wider context.

More news and analyses on Amgen stock